BURLINGTON, Mass. — PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based global biopharmaceutical company, announced it has signed an investment agreement to build a new manufacturing facility in Toa Baja, Puerto Rico, marking a key step in its plan to establish dual production sites in Taiwan and the United States.
The agreement, signed March 26, is part of the company’s broader strategy to strengthen supply chain resilience and support long-term growth through a dual-site manufacturing network.
The signing ceremony drew a range of officials from Puerto Rico, the United States, and Taiwan, highlighting the growing collaboration between the two regions in life sciences manufacturing and innovation.
Chairperson Dr. Ching-Leou Teng said the project represents more than a business expansion.
“This is not just a closing — it is the start of a long-term partnership and a clear demonstration of our commitment to patients,” Teng said.
Puerto Rico Governor Jenniffer González Colón said the investment reinforces the island’s standing as a hub for advanced pharmaceutical manufacturing.
“This investment reaffirms Puerto Rico’s position as a reliable and competitive U.S. jurisdiction for advanced biopharmaceutical manufacturing. We continue to attract projects that strengthen our economy, create specialized jobs, and contribute to the resilience of the United States’ supply of critical medicines,” González Colón said.
Chi Yu Chou, director general of the Taipei Economic and Cultural Office in Miami, said the project reflects deepening economic ties between Taiwan and the United States.
“The company’s dual production strategy embodies the symbiotic partnership between the two sides, as emphasized by Foreign Minister Lin Chia-lung. This project demonstrates the breadth and resilience of Taiwan’s industries, extending beyond AI and semiconductors into biotechnology and healthcare. It also underscores the potential for deeper bilateral economic cooperation and the continued global competitiveness of Taiwanese enterprises in high-value sectors,” Chou said.
The Puerto Rico facility will be built to the same standards as PharmaEssentia’s manufacturing site in Taichung, Taiwan, with a focus on improving production efficiency and reducing risk across its operations. Employees at the new site will undergo training in Taiwan to support knowledge transfer and operational readiness.
The company expects the facility to begin operations in 2027, pending regulatory approvals.
Founder and Chief Executive Officer Dr. Ko-Chung Lin said expanding manufacturing beyond Taiwan is central to the company’s strategy.
“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia,” Lin said. “We are proud to establish U.S.-based manufacturing, with Puerto Rico serving as a key hub to support the U.S. market and our commitment to patients worldwide – including those benefiting from BESREMi® (ropeginterferon alfa-2b-njft).”
